Age >75 + ECOG ≥2 OR significant comorbidity — pentostatin's weekly schedule allows finer...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-HCL-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-HCL |
| Sources | SRC-ESMO-DLBCL-2024 SRC-NCCN-BCELL-2025 |
Red Flag Origin
| Definition | Age >75 + ECOG ≥2 OR significant comorbidity — pentostatin's weekly schedule allows finer toxicity titration than cladribine 5-7 day continuous infusion; preferred for fragile patients. |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
| Shifts algorithm | ALGO-HCL-1L |
Trigger Logic
{
"all_of": [
{
"any_of": [
{
"comparator": ">",
"finding": "age_years",
"threshold": 75
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
},
{
"comparator": ">=",
"finding": "ecog_status",
"threshold": 2
}
],
"type": "composite_clinical"
}
Notes
Pentostatin's weekly cadence permits adjustment between doses; cladribine's 5-7-day infusion is committed. For elderly frail, pentostatin's tolerability advantage outweighs cladribine's slightly higher CR rate.
Used By
Algorithms
ALGO-HCL-1L- ALGO-HCL-1LALGO-HCL-2L- ALGO-HCL-2L
Indications
IND-HCL-2L-VEMURAFENIB- IND-HCL-2L-VEMURAFENIB